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Although researchers have identified genetic alterations that contribute to development of 
esophageal adenocarcinoma, we know little about features of patients or environmental 
factors that mediate progression of chronic acid biliary reflux to Barrett’s esophagus and 
cancer. Increasing our understanding of the mechanisms by which normal squamous 
epithelium progresses to early-stage invasive cancer will help formulate rational surveillance 
guidelines and allow us to divest resources away from patients at low risk of malignancy. We 
review the cellular and genetic alterations that occur during progression of Barrett’s 
esophagus, based on findings from clinical studies and mouse models of disease. We review 
the features of the luminal and mucosal microenvironment of Barrett’s esophagus that 
promote, in a small proportion of patients, development of esophageal adenocarcinoma. 
Markers of clonal evolution might be used to determine patient risk for cancer and set 
surveillance intervals. 
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Although esophageal adenocarcinoma (EAC) is rare in many parts of the world, its incidence 
has increased 4%–10% each year in developed countries since the 1970s
1
. Median survival 
times are short, chiefly because most patients are diagnosed with advanced-stage disease 
that is not curable
2
. EAC prevalence therefore closely follows its incidence. Barrett’s 
esophagus (BE), defined as the replacement of the squamous epithelial lining native to the 
esophagus by metaplastic columnar epithelium, is a well-established risk factor for EAC
3
. 
Acid biliary reflux from the stomach leads to development of BE, the initial step in 
progression to EAC, which can be tracked by histologic and genetic changes
4
.  
 The increase in EAC incidence appears to be a result of the increased prevalence of 
BE
5
. The exact population prevalence of BE is difficult to establish, because this disease does 
not produce symptoms and because of the weak association between reflux complaints and 
BE
6
. Furthermore the operative definition of BE is not consistent among expert guidelines, 
so the true prevalence is unclear
7
. Notwithstanding these caveats, population estimates of 
BE range from 1% to 5%
8, 9
.  
Retrospective population-based studies found that rates of progression from BE to 
cancer to range from 0.10% to 0.13% per year 
10, 11
, indicating that BE is mostly a long-term 
benign condition
12
.  Many patients in surveillance programs are therefore needlessly 
exposed to the risks and negative effects of routine screening. The flip side to this argument 
is that BE is an under-diagnosed condition, because more than 85% of patients with newly 
diagnosed EAC have no history of either BE or heartburn complaints
6, 13
. For this reason, the 
clinical return (and cost-benefit) of BE surveillance programs are subject to scrutiny. Trials 
such as the British Barrett’s Oesophagus Surveillance Study and the BarrettNET registry (in 
Munich, Germany), comprising more than 5000 patients to be followed for more than 10 
years, aim to compare all-cause and disease-specific mortality between patients who have 
been randomly assigned to groups that will undergo endoscopic surveillance every 2 years 
vs patients with a more conservative clinical follow up. Hopefully findings from these studies 
will provide some guidance on this issue
14
. The sample size and length of follow up of these 
trials are a clear indication of the complexity and magnitude of this endeavor.  
 In BE, the inflammatory microenvironment and somatic genomic alterations in stem 
cell populations are believed to mediate progression to EAC. We review the mechanisms by 
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mouse models of BE
20, 21
. The adaptive nature of BE indicates that forces of natural selection 
act on tissue-specific stem cells, causing changes that lead to tumorigenesis.  
 
Progression From Reflux Esophagitis to BE, Based on Histology 
The seemingly straightforward histopathologic definition of BE as a metaplastic condition 
whereby the native squamous epithelium of the distal esophagus is replaced with columnar 
epithelium belies an altogether far more complex microscopic process. Biopsies from 
patients contain a range of columnar phenotypes. Despite emphasis on the cellular 
composition of the epithelium, the BE segment is organized, like all mucosal layers of the 
gastrointestinal tract, into a quasi-repetitive arrangement of glands. Every gland is 
maintained by a unique population of stem cells and can therefore be thought of as a 
singularly evolving unit within the mucosal sheet. These metaplastic glandular units have a 
variety of appearances. However, morphologies of the various types of glandular units do 
not vary within or among patients—they often resemble gland types found elsewhere in the 
gastrointestinal tract, either in healthy individuals or patients with gastrointestinal disease.  
 The gland phenotype most commonly associated with BE has a mixed epithelial 
lining comprising scattered goblet cells against a background of columnar cells with 
properties that are indistinguishable from gastric foveolar cells (Figure 1A and B). This dual 
pattern of epithelial differentiation is reflected in its mucin core peptide and expression 
pattern of trefoil factor (TFF), with goblet cells producing the intestinal type mucin (mucin 2, 
oligomeric mucus/gel-forming, MUC2) as well as TFF3, whereas foveolar cells produce the 
gastric type mucin (MUC5AC) and TFF1
22
. These MUC proteins contain abundant 
oligosaccharide side-chains, which allow these proteins to bind copious amounts of water 
after secretion into the gut lumen. These MUC proteins further self-aggregate, which creates 
a visco-elastic gel that coats the underlying epithelium
23
. This peculiar pattern of mixed 
gastric and intestinal lineage differentiation has been widely described as specialized 
epithelium or specialized metaplasia, or, simply, intestinal metaplasia. Older publications 




 In crypts in the small intestine and colon, stem cells reside strictly at the base of the 
gland and move up along the crypt (and villus) as they differentiate and mature. In BE 
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the gland; mature cell lineages show bidirectional flow from this stem cell compartment 
towards the lumen as well as towards the base of the gland. This was demonstrated in a 
study of patients with EAC scheduled for esophageal resection. Patients were given an 
infusion of a thymidine analogue at different timepoints before surgery
22
. Tracing the 
distribution of this indelible label in daughter cell populations confirmed bi-directional 
migration within BE glands and showed that cell migration toward the glandular base 
compartment of the gland occurred much more slowly than toward the superficial crypt 
compartment of the gland. The label had been all but lost from the superficial crypt 
population in little over a week, whereas non-dividing cells that contained the thymidine 




The mucous base of the BE gland is lined by a population of columnar cells that 
express MUC6 and also secrete bicarbonate (HCO3
–
). This buffers the caustic refluxate and, 
together with the mucinous gel that covers the metaplastic mucosa, protects the lining of 
the distal esophagus. It is important to be aware of this functional compartmentalization to 
understand the unique functional properties of the BE gland
26
.  
 Expression of LGR5, a marker of stem cells, about one-third up the height of the 
gland provides support for this location of the stem cell niche
22
. LGR5 mRNA is detected at 
the junction of the MUC5AC+ and TFF1+ cells and the MUC6+ and TFF2+ cells, the origin of 
the bidirectional cell flux and site of maximum proliferative activity (shown by 
immunohistochemical analysis for Ki-67, see Figure 1). These observations help us to 
understand the cells and their functions in the BE gland. It is important to note that this bi-
directional compartmentalization is not unique to the metaplastic esophagus —it resembles 
the basic architecture of the pyloric gland in the normal gastric antrum.  
 There are a small numbers of other gland types, which together constitute the 
metaplastic mosaic of the columnar esophagus (see Figure 2). Best studied of these is the 
cardiac gland (also transitional gland or non-goblet columnar gland). In essence, the 
epithelial lining and bidirectional architecture of the cardiac-type gland are identical to those 
of the BE gland, except for an absence of goblet cells in these glands. This makes the cardiac 
gland the simplest, in terms of differentiated epithelial cell types, of all BE gland types. The 
cardiac gland contains only MUC5AC+ and TFF1+ foveolar cells along the superficial crypt 
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studied extensively, because they are the type most commonly found in biopsies of patients 
with short-segment BE and in biopsies from patients with columnar metaplasia of the neo-
distal esophagus following esophageal resection. This gland type may be the earliest 
detected during development of BE. It is also indistinguishable, in terms of glandular 
architecture and cell composition, from reparative glands (known as pseudo-pyloric 
metaplasia) found in, for example, terminal ileitis in patients with Crohn’s disease. 
 The remaining gland types are variations on a theme. The cardiac type gland may 
show oxyntic differentiation in the form of scattered parietal cells, at which point the gland 
is essentially comparable to similar glands found in the transitional mucosa of the gastric 
incisura or gastric pylorus (see Figure 2). Contrary to common belief, parietal cells are not 
restricted to corpus mucosa and are abundant in normal pyloric mucosa
27
. Mature chief cells 
are also found in these glands, which contain the complete complement of cell types 
normally found in the gastric body and fundus, although the irregular packing of these 
glands indicates that this is non-native, post-inflammatory mucosa. In many patients, these 
glands are found in the context of anatomic features of the esophagus such as submucosal 
gland complexes, so these fundic-type glands develop as part of the metaplastic mosaic. It is 
important to determine whether these metaplastic oxyntic glands develop from cardiac 
glands and, if so, whether they are true stem-cell derived metaplasias or a manifestation of 
varying levels of oxyntic gland differentiation. Varying levels of differentiation of these 
archetypal gastric glands have important implications for the temporal dynamics of 
glandular metaplasia in the atrophic stomach.  
 Some glands have mature intestinal differentiation, with Paneth cells at the base and 
enterocytes along the superficial crypt compartment (Figure 2). These are the only glands 
that completely lack gastric mucin core proteins; they are also the most rare of gland types 
described. However, tissues from some patients have high levels of Paneth cell 
differentiation.  
 Remarkably, the distribution of these gland phenotypes is not random—they appear 
in recurrent temporal and spatial patterns along the BE segment. Intestinal phenotypes are 
found more proximally at the squamo-columnar junction, whereas cardiac and 
oxyntocardiac gland phenotypes are proportionally more common around the gastro-
esophageal junction 
28-30
. For example, Harrison et al found that intestinal differentiation 
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compared to the biopsies collected from the gastro-esophageal junction, with a clear 
stepwise gradient in between
29
. The density of glands containing intestinal differentiation 
correlates with the pH gradient along the BE segment; the less acidic the local average pH 




The functional significance of this spatial distribution of gland phenotypes is unclear. 
We proposed that this distribution in gland types could result from local selection for cells 
that can survive in the harsh environment of the acid biliary refluxate at the distal 
esophagus
26
. The soluble component of bile acids, which acts as a detergent and solubilizes 
lipid cell membranes through micelle formation, could be responsible for this environment. 
Studies of bile salt solubility found it to be greatest at intermediate luminal pH ranges seen 
most proximally, whereas bile acids are insoluble and therefore incapable of forming 
micelles at lower pH ranges in the distal esophagus
31, 32
. In vitro studies have shown that 
solubilized duodenal bile salts are a strong inducer of CDX2 expression and goblet cell 
differentiation
33-35
. The pH gradient along the BE segment could therefore create a 
proximal–distal gradient of bile salt solubility, which could determine the relative proportion 
of specific gland phenotypes along the length of the esophagus.  
Temporal analysis of gland phenotype distribution is complicated because, in most 
patients, the BE segment is static over time and does not expand (or contract) despite years, 
or in some cases decades, of endoscopic follow-up evlaluations
36
—even in patients with 
continued esophageal exposure to acid biliary reflux
37
. However, patients that have 
undergone cardia-esophagectomy because of esophageal cancer lose normal sphincter 
function, which provokes severe gastro-esophageal reflux. Consequently, about half of 
these patients develop columnar mucosa in the remnant distal esophagus de novo. 
Longitudinal studies found that the length of columnar mucosa increases over time 
and histopathologic analyses demonstrated that the glandular phenotype changes from 
purely cardiac-type mucosa to BE glands, with intestinal differentiation
38-40
. These 
observations indicate that the mucous cardiac-type gland is the earliest gland phenotype 
that develops in the reflux-damaged distal esophagus; it might change to either an intestinal 
(goblet cells and Paneth cells) or gastric (parietal and chief cells) lineage differentiation 
(Figure 2). In support of this model, some studies have shown cardiac type glands to 
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Studies have shown clonal ancestry of canonical specialized BE glands and non-intestinalized 
cardiac-type glands—these various phenotypes do not develop independently, but arise via 
phenotypic variation within glands derived from a common ancestor
18
.  
Progression from cardiac-type glands to intestinalized epithelium was demonstrated 
in a mouse model of BE (EBV-L2-IL1B mice). These mice overexpress interleukin 1 beta (IL1B) 
in the esophageal and squamous forestomach epithelium, and develop spontaneous 
esophagitis that progresses to metaplasia at the gastro-esophageal junction and 
adenocarcinoma with older age
20
. Addition of bile acids (0.2% deoxycholic acid) to their 
drinking water accelerates onset of intestinal metaplasia and tumorigenesis. Metaplastic 
esophageal tissues from these mice have increased levels of TFF2, CCKBR, MUC5AC, CDX2, 
and K19, compared to esophageal tissues of control mice. In EBV-L2-IL1B mice, bile acids 
lead to demethylation of gene promotor regions, leading to increased expression of IL6, 
CDX2, and Notch
43, 44
, promoting commitment to the intestinal cell lineage. The earliest 
morphologic manifestation of glandular differentiation in the distal esophagus therefore 
appears to be the simple cardiac-type gland, which can evolve with time into either an 
intestinal or gastric cell glandular phenotype.  
 What promotes columnar transformation of the distal esophagus when acid biliary 
reflux first hits the naïve squamous mucosa of the distal esophagus? This is a question of 
great contention and one on which opinion is sharply divided. Several models have been 
proposed, but 2 models that have (arguably) been studied most. The transdifferentiation 
model proposes that squamous stem cells with chronic exposure to the corrosive effects of 
acid-biliary reflux slowly change their differentiation lineage, downregulating the native 
squamous expression program and upregulating a columnar cell expression program via 
upregulation of lineage-determining factors such as SOX9
34, 45, 46
. Support for this model 
comes from a trial of patients with reflux successfully treated with proton pump inhibitors 
(PPIs) who discontinued acid suppression for 2 weeks
47
. In this relatively short time period, 
all patients had progressive symptoms—some with severe erosive (Los Angeles Grade C) 
reflux esophagitis. Biopsies from non-eroded areas were infiltrated by large numbers of 
lymphocytes, so inflammatory cells might contribute to pathogenesis. 
 In the chronic wounding model, continuous micro-trauma, due to caustic reflux, 
erodes small patches of squamous epithelium, which are repaired by the wound-healing 
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to cover the epithelial defect. Wounding at the squamo-columnar junction elicits 
proliferation of squamous and columnar progenitors on either side of the epithelial defect. 
This is recognizable as a thin layer of undifferentiated epithelial cells covering a fresh wound 
bed (Figure 3A). Although this is essentially a stereotypical wound healing response, 
exposure to reflux promotes selection for phenotypes best adapted to the harsh 
environment, such as mucin-producing columnar progenitors. With recurrent bouts of reflux 
and ulceration, the columnar epithelium expands, progressively replacing the distal 
esophageal squamous epithelium (Figure 3B-F).  
 Lineage tracing experiments in mouse models of BE indicate that metaplastic lesions 
originate from stem cells in the gastric cardia
20, 28, 48
, which over time expand proximally into 
the squamous esophagus, replacing squamous epithelia (Figure 4). This progression 
associates with development of dysplasia in the mice. Expansion seems to occur first in the 
cardia, presumably in response to inflammatory cytokines, in contrast to esophageal injury 
without reflux, leading to squamous lineage regeneration through Ker15-negative cells
49
. 
The esophageal microenvironment and signaling pathways regulate tissue regeneration and 
cell fate decisions. In summary, a pool of stem cells in a niche at the gastro-esophageal 






 in mice) expands and, with the 
development of genomic instability, enters a phase of clonal evolution that proceeds over a 
period of years and, in some patients, resulting in EAC.  
 It is not clear whether cyclic wounding and expansion occurs within a short time 
period or progresses over many months or years. Progressive widening of the lower 
esophageal sphincter, due to slowly increasing abdominal pressure and increased reflux, 
might progressively erode the distal esophageal epithelium over many years. There is some 
(indirect) evidence for this from studies of patients
51
. For example, in carefully executed 
studies analyzing esophageal reflux by detailed pH and manometry measurements across 
the lower esophageal sphincter, McColl et al found that, in patients with a large waist 
circumference, acid reflux extends more proximally into the lower esophageal sphincter. 
Importantly, this correlated with a longer zone of cardiac-type columnar mucosa at the 
gastro-esophageal junction
52
. Furthermore, in some patients, the histologic 
squamocolumnar junction can actually move distally, covering the gastric cardia. Derakhshan 
et al observed this phenomenon in a patient with long-standing atrophic gastritis and 
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resection specimen clearly showed a collar of squamous epithelium, which occupied the 
anatomic cardia
53
. Given the atrophic gastritis, the most parsimonious explanation is that in 
this case, due to continuous erosion of the friable gastric mucosa, the squamous epithelium 
outcompeted native glands in the proximal stomach.  
  
A Permissive Environment for Esophageal Carcinogenesis 
Identification of environmental factor that contribute to carcinogenesis might facilitate 
patient risk stratification for surveillance programs (see 
54
 for review)—especially because 
reasons for the rapid increase in incidence of BE and EAC are unclear
55
. Environmental 
factors might partially explain the increased incidence,
56
 given that BE is rare in children and 
adolescents
57
 and life style changes appear to mediate the increase in BE incidence in the 
Far East
58





, and stress levels
62, 63
. Male sex and older age are consistently 
identified as covariates and this association persists irrespective of ethnic background and 
nationality
64, 65
. The most proximate risk factor for BE and EAC likely is chronic reflux and 
associated conditions such as hiatal hernia or esophagitis
66
. The effects of chronic reflux are 
likely to vary among patients, provoking in some individuals an inflammatory 
microenvironment promotes cancer development.  
 Drugs such as PPIs, non-steroidal anti-inflammatory drugs (NSAIDs), and statins also 
affect risk of BE and progression to EAC
67-69
. PPIs are used routinely to treat patients with 
reflux symptoms and promote esophagitis healing
70
. Although epidemiologic studies have 
found PPIs to reduce the risk of BE progression
71
, no randomized placebo-controlled trials 
have shown PPIs to have chemopreventive effect. There has been some inconsistency with 
regard to the effects of PPIs on risk of progression risk; some studies reported decreased 
risk
72
 and others reported increased risk of progression
73, 74
. Reports of increased risk of 
esophageal cancer in patients taking PPIs could result from bias in reporting or indicate that 
micro-environmental changes cause competitive release of incipient neoplastic clones. A 
study in the EBV-LR-IL1B mouse model of BE found PPI-induced hypergastrinemia and 
genetic hypergastrinemia to increase development of columnar metaplasia of the esophagus 
and accelerate progression to dysplasia
50
. In patients, PPIs also induce secondary 
hypergastrinemia
75, 76
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 The increasing incidence of BE and EAC have also been associated with improved 
sanitation and the consequent decrease in gastric Helicobacter pylori, mainly in the West
78, 
79
. Although the inverse correlation between EAC incidence and H pylori infection may relate 
strictly to decreased acid output (hypochlorhydria) and reflux
80
, H pylori colonization also 
significantly alters the native gastric flora and the esophageal flora. The bacterial 
community of the normal esophagus
81
 changes in patients with reflux-related disorders and 
BE 
82, 83
 or patients receiving PPI therapy
84
.  
 The common denominator of these environmental factors (constitutional, diet, and 
drug-related) is that they affect the local BE micro-environment. In some individuals, the 
combination of esophageal inflammation and genetic factors could promote BE progression 
and carcinogenesis. 
 
Inflammation Promotes Esophageal Carcinogenesis 
The tissue microenvironment promotes some of the earliest events in esophageal tumor 
development (Figure 4). Tissue-specific stem cells are believed to retain their 
undifferentiated state through physical proximity with a dedicated niche 
85, 86
. Stem cell 
proliferation and differentiation at the gastro-esophageal junction could be regulated by 
signaling pathways that are active throughout the mammalian gut, such as the Wnt, Notch, 
bone morphogenetic protein, and hedgehog pathways
87
. We discussed how chronic 
wounding in a harsh environment can induce cephalad expansion of columnar epithelia into 
the esophagus, but little is known about the mechanisms of this process and subsequent 
tumorigenesis.  
Inflammatory cells release signaling molecules that promote and accelerate tissue 
healing, but simultaneously establish a carcinogenic microenvironment, by increasing local 
tissue concentrations of mutagenic oxygen and nitrogen species
88, 89
. Studies in mouse 
models have provided evidence for the interaction between the inflammatory 
microenvironment and tumor-initiating stem cells. Induction of IL1B and IL6 by bile acids 
leads to inflammation and activates gastric cardia stem cells, which promote columnar-like 
metaplasia of the distal esophagus and cell changes that result in dysplasia
20
. Inflammation 
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It will be a challenge to characterize the cells and signaling pathways involved in these 
processes, but increasing our understanding these mechanisms could lead to development 
of chemopreventive agents such as NSAIDs.  
 IL1b, IL6, and IL8, are upregulated in BE—particularly at the cardia
90
. In mice, 
expression of IL1B induces chronic inflammation and dysplastic changes that require IL6. 
These cytokines are upregulated in different types of preneoplastic tissues and tumor 
microenvironments, in association with activation of nuclear factor (NF)-κB and are involved 
in development of BE and EAC
20
. Inflammatory cytokines including interferon gamma (IFNG), 
Il1B, IL6, and IL8, are expressed by epithelial cells in response to acid and bile reflux and 
attract inflammatory cells including tumor-associated macrophages, neutrophil 
granulocytes, myeloid-derived suppressor cells, immature myeloid cells,
91
 mast cells, and 
adaptive immune T and B cells
92
. Activation of a T-helper (Th) 1 cell response, characterized 
by production of IFNG, has been associated with acid reflux-induced esophagitis
90, 93
. This 
Th1 response found in esophagitis can change to a Th2 profile as BE is established. This shift 
is associated with an increase in IL4-producing Th2 cells and local increases in IL6. Finally, 
increases in inflammatory and anti-inflammatory cytokines, but fewer T cells, were found in 
EAC biopsies, compared with non-tumor tissues, indicating mixed inflammatory profile at 
this advanced disease of stage
94
. 
 Progression from ulcerative esophagitis to BE might therefore be accompanied by a 
shift in cytokine expression patterns. Myeloid and dendritic cells are recruited during 
esophageal progression of metaplasia to dysplasia and carcinoma. In the mouse model of 
BE, IL1B induces columnar metaplasia, in part, through recruitment of immature myeloid 
cells
20
. Furthermore, a CDX2-dependent reduction in a subpopulation of immature myeloid 
cells with immune suppressor properties prevents dysplasia
95
. Epithelial CDX2 might 
therefore protect against disease progression by limiting the production of the immature 
myeloid cells. Cardia and esophageal tissues from EBV-L2-IL1B mice given bile acids to 
accelerate BE development have a shift in myeloid phenotype towards granulocytic 
differentiation. Mixed acute (granulocytic) and chronic (IL1B) inflammatory responses might 
therefore accelerate carcinogenesis
20
. In mice, a myeloid subtype of the CD11b+Ly6G+ 
granulocyte lineage, tumor-associated neutrophils, support tumor growth by producing 
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 The tumor stroma contains mesenchymal cells, which might increase proliferation of 
nearby epithelial cells or recruit and polarize cells of the adaptive and innate immune 
system into those that promote tumorigenesis 
98, 99
. There is evidence from preclinical and 
clinical studies that mesenchymal cells contribute to the development of gastrointestinal 
cancers
100-102
 and are associated with  gene expression patterns that increase inflammation 
103
.  
 The composition of the human microbiome changes with and affects many human 
diseases, including cancer development
104
. The esophagus contains a complex but 
conserved population of resident microbes, with an estimated 140 bacterial species—95 of 
which have been identified
81
. The esophageal microbiome changes in patients with reflux-
related disorders or BE, compared to healthy individuals 
82
. Esophageal microbial diversity 
decreases and community composition is altered in patients with EAC, including decreased 
Gram-negative (Veillonella, Megasphaera, and Campylobacter) and Gram-positive taxa 
(Granulicatella, Atopobium, Actinomyces, and Solobacterium) and increased Lactobacillus 
fermentum. However, researchers found no significant differences in the microbiomes of 
samples of BE or EAC compared to healthy esophageal tissue 
105
. There is no clear evidence 
that 1 particular species contributes to progression of BE. However, given the differences in 
species composition between patients with vs without EAC, a small community of microbial 
species might contribute to carcinogenesis, or could simply result from it. In either case, 
distinct microbial ecotypes be biomarkers of patients at risk.  
 The World Health Organization has classified H pylori as a class I carcinogen because 
of its role in gastric adenocarcinoma development. It is estimated that over half of the 
world’s population is infected with H pylori
106
. There are however well-documented 
disparities in global H pylori prevalence and the inverse correlation between regional gastric 
cancer risk and EAC risk
6
. Given that H pylori infection provokes chronic atrophic gastritis and 
hypochlorhydria, it is thought that H pylori can decrease the effects of environmental risk 
factors, such as chronic reflux, to decrease EAC risk.  
 Patients with BE who are infected with H pylori have slower rates of aneuploidy and a 
non-significant trend towards lower incidence of EAC
107
. The composition of the gastric 
microbiome might therefore affect carcinogenesis in the distal esophagus. In patients with 
reflux esophagitis, the microbiomes of the esophagus and the stomach, particularly the 
pyloric antrum, overlap in microbial composition
107
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dominate the upper gastrointestinal tract, but the ratio of these species has also been 
associated with waist-to-hip ratio and hiatal hernia length. There could be interactions 
among modifiable risk factors. Importantly, in addition to a possible direct genotoxic effect 
on the junctional epithelium, an esophageal barrier defect can lead to translocation of non-
pathogenic bacteria, which affects immune homeostasis by shifting the balance towards 
tumor-promoting immune responses, similar to the proposed effects of bile acids.  
 Bacterial products are sensed by receptors such as the toll-like receptors and NOD-
like receptors. Activation of these pathways leads to the production of chemokines, 
inflammatory cytokines, and anti-microbial peptides
108, 109
. Wnt activation leads to barrier 
defects that cause aberrant expression and mislocalization of tight junction proteins, 
including occludin and claudins in epithelial cells, and downregulate production of 
protective mucins, which occurs during esophageal carcinogenesis
110
. Bacterial invasion of 
the esophagus and gut in general could induce an inflammatory response that involves 




Progression of BE to EAC  
The cell intrinsic and extrinsic microenvironments of BE inevitably contribute to clonal 
evolution in BE tissues that sometimes leads to the development of EAC. Studying BE is a 
good way to study carcinogenesis in general, because biopsies are collected from patients 
over long time periods and provide records of changes that occur during tumorigenesis (see 
Figure 5A-C). 
 Analyses of genomic heterogeneity in BE have provided support for the clonal origin 
of the metaplasia. Genotype analyses of biopsies from the Seattle Barrett’s Esophagus 
cohort have found the BE segments to contain clonal alterations at the CDKN2A (chr 9p) 
locus (encodes p16) 
112
. Genome-wide copy number analyses indicated that large-scale 
somatic mutations at fragile sites also tended to be clonal across the segment
113
. Although 
these large clones could have been formed by expansion of late-arising mutant clones, 
through an already established BE esophagus segment, a more parsimonious explanation is 
that the founder BE cells had already acquired these genomic changes. 
 Except for the few founder lesions, BE tissues that do not progress to cancer acquire 
few alterations to genome structure (copy-number alterations or loss of heterozygosity 
events)
113


















, often mediated by TP53 inactivation, leading to genome doubling
15
 
followed by the rapid development of EAC. Single nucleotide alterations (SNAs), on the other 
hand, appear to accrue continually in benign and dysplastic tissue; except for the TP53 and 
SMAD4 genes, genic SNAs are not stage specific
114
. Moreover, apart from TP53 and SMAD4 
genes, there is no compelling evidence that cells with SNAs have a selective advantage, and 




 BE appears to arise from a clone with a stable genome, and thereafter, cells with 
genome structural alterations (large-scale losses, gains, and rearrangements in the genome) 
but not SNAs, are selected. In most patients, there is no evidence of ongoing important 
evolution, so BE can be thought of as an evolutionarily indolent condition (Figure 5 D and E). 
It is plausible that the initial BE lesion is well-adapted to the microenvironment, such that 
slight alterations to the genotype or phenotype of BE cells (or glands)—those changes 
mediated by most SNAs—are not sufficiently advantageous to expand. In contrast, 
alterations in chromosome structure could cause changes in cell phenotypes—they are 
associated with dysplasia after all
15, 113
 —and be selected. Consistent with the concept that 
few clones undergo strong positive selection, a longitudinal study of 195 patients with BE 
found that the level of clonal diversity across the entire BE segment (as measured by single-
cell genetic analysis of endoscopic brush specimens) to be typically fairly constant over 




 These evolutionary dynamics have important ramifications for the development of 
biomarkers to predict EAC development. Changes in genome structure are more likely to 
identify patients at risk for progression than SNAs alone. More importantly, the level of 
clonal diversity across a BE segment could be used as a marker of risk for EAC, with higher 
diversity associated with increased risk
117
. Because the level of clonal diversity does not 
change over time, the baseline level of diversity indicates a similar level of cancer risk to 
measurements made years later
116
. Moreover, the typical time it takes for a new clone to 
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A method to identify patients with BE most likely to progress to EAC would allow us to 
allocate resources on those at risk and avoid unnecessary procedures for those at low risk. 
Increasing our understanding of the pathogenesis of BE, including its clonal origin and early 
stages of progression to EAC, could lead to identification of biomarkers of risk. There are 
multiple competing models for the early development of BE and each of these has gained 
significant traction in recent years. This is an exciting field of research and an integrated 
approach will allow us to advance more rapidly. Evidence from studies of patients and 
mouse models indicates a sequence of changes in gland phenotypes, first initiated through a 
wounding and competitive replacement scenario. Lineage tracing data from a mouse model 
of BE corroborates this sequence of events. Genetic screens and new mouse models are 
needed to determine the features of patients, the immune response, and the luminal 





















Figure 1 The Specialized BE Gland  
A) Standard H&E-stained section of BE metaplasia showing goblet cells (arrowheads) along 
the superficial crypt compartment of the gland and mucous cells (arrows) lining the base of 
the gland. B) Cartoon of the glands shown in A. The goblet and foveolar cells are shown in 
pink, whilst the mucous base cells are shown in azure, and the gland’s stem cells are shown 
in magenta.  
 
Figure 2. Gland Phenotypes in the Metaplastic Mosaic of the BE mucosa  
The top row shows photomicrographs of representative gland types in H&E-stained sections. 
The constituent cells of the various glands are indicated (details in the main text). The lower 
half of the panel shows cartoons of the various gland types with main cell types as shown 
below. The non-goblet columnar gland is the simple mucous gland of cardiac mucosa and it 
is the first gland of columnar metaplasia in the distal esophagus. Over time this pioneer 
gland may change and follow different lines of differentiation, along either gastric or 
intestinal pathways. Together these gland phenotypes constitute the metaplastic mosaic of 
BE mucosa. 
 
Figure 3 Models of Wounding and Competitive Replacement for Development of BE  
A) Low power overview (left) of the squamo-columnar junction in a BE segment. The 
columnar and squamous epithelia are indicated. Note the submucosal gland complexes, 
which confirm that this represents bona fide columnar metaplasia of the distal esophagus. 
High-power view of the squamocolumnar junction (right). The stroma shows granulation 
features indicative of recent epithelial denudation. The overlying epithelium is a single layer 
of proliferative, undifferentiated epithelium covering this defect. The squamous and 
columnar epithelium can be clearly identified on either end. This undifferentiated 
epithelium may derive from either squamous or columnar epithelial progenitors, but the 
corrosive acid-biliary reflux micro-environment will drive secondary selection for 
phenotypes best adapted to this harsh ecology thus favoring mucin-producing columnar 
progenitors. Lineage tracing experiments in mouse models (see also Figure 4) indicate that 
this undifferentiated layer of epithelium is clonally derived from the adjacent columnar 
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stomach and esophagus. C) Chronic acid-biliary reflux damages and progressively erodes the 
native squamous epithelium leading to an ulcerative defect. D) This defect is covered with a 
single layer of undifferentiated epithelium as shown in A. E) Following selection, the 
epithelial progenitors mature as mucous glands. F) With time these mucous glands undergo 
various lines of differentiation, either intestinal (shown) or gastric, depending on the local 
micro-environment. With recurrent bouts of reflux and ulceration, the columnar epithelium 
expands, progressively replacing the distal esophageal squamous epithelium. 
 
Figure 4 Inflammation and the Luminal Niche Promote Expansion of Columnar Progenitors 
from Proximal Stomach  
A) The squamocolumnar junction coincides with the anatomic junction of stomach and 
esophagus. Stem cells within glands in the proximal stomach are indicated in orange B) Acid 
biliary reflux, possibly in conjunction with dysbiosis in the luminal niche, promote expansion 
of columnar progenitors. The reparative epithelium carries the clonal mark of glands within 
the proximal stomach. This situation mimics the lineage tracing data obtained from a mouse 
model of BE. Inflammation is indicated. C) With time this reparative epithelium matures as 
columnar glands through secondary selection for mucin-producing phenotypes. 
 
Figure 5 Dynamic Equilibrium and Clonal Stasis During Carcinogenesis 
A) A BE lesion shown in the distal esophagus. B) Endoscopic view of the BE segment 
(endoscopy picture courtesy of Rehan Haidry). C) The BE segment is a mosaic of glandular 
clones, which expand and contract over time. Subclones are visualized as colored patches 
within the BE segment. D) A diagram of the unfolded esophagus showing a BE segment 
(left). Every gland within the segment is maintained by a unique population of stem cells and 
can be thought of as a singularly evolving unit within the mucosal sheet. These gland units 
are shown as hexagons. Patches of colored hexagons denote subclones within the clonally 
derived BE segment. These clonal patches may contract or expand over time and the overall 
pattern is therefore consistent with dynamic equilibrium (middle). On rare occasions, some 
clones are transformed and contribute to tumorigenesis (right). E) Clonal abundance and 
diversity within the BE segment over time. The y-axis shows the clone size within the 
segment and the x-axis shows time. The parent clone to take hold within the segment has 
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subclones arise that can recede or expand over time. One clone sustains a biallelic mutation 
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